Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 7(1): 8696, 2017 08 18.
Article in English | MEDLINE | ID: mdl-28821749

ABSTRACT

Multiple Sclerosis (MS) is an immune-mediated demyelinating disease of the human central nervous system (CNS). Memory impairments and hippocampal demyelination are common features in MS patients. Our previous data have shown that demyelination alters neuronal gene expression in the hippocampus. DNA methylation is a common epigenetic modifier of gene expression. In this study, we investigated whether DNA methylation is altered in MS hippocampus following demyelination. Our results show that mRNA levels of DNA methyltransferase were increased in demyelinated MS hippocampus, while de-methylation enzymes were decreased. Comparative methylation profiling identify hypo-methylation within upstream sequences of 6 genes and hyper-methylation of 10 genes in demyelinated MS hippocampus. Genes identified in the current study were also validated in an independent microarray dataset generated from MS hippocampus. Independent validation using RT-PCR revealed that DNA methylation inversely correlated with mRNA levels of the candidate genes. Queries across cell-specific databases revealed that a majority of the candidate genes are expressed by astrocytes and neurons in mouse and human CNS. Taken together, our results expands the list of genes previously identified in MS hippocampus and establish DNA methylation as a mechanism of altered gene expression in MS hippocampus.


Subject(s)
DNA Methylation/genetics , Demyelinating Diseases/genetics , Hippocampus/pathology , Multiple Sclerosis/genetics , Aged , Animals , CpG Islands/genetics , DNA (Cytosine-5-)-Methyltransferases/metabolism , Demyelinating Diseases/pathology , Female , Humans , Male , Mice , Middle Aged , Myelin Sheath/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transcription Initiation Site
2.
Acta Neuropathol Commun ; 2: 98, 2014 Aug 23.
Article in English | MEDLINE | ID: mdl-25149422

ABSTRACT

A remarkable pathological difference between grey matter lesions (GML) and white matter lesions (WML) in Multiple Sclerosis (MS) patients is the paucity of infiltrating leukocytes in GML. To better understand these pathological differences, we hypothesize that the chemokine monocyte chemotactic protein-1 (MCP-1 or CCL2), of importance for leukocyte migration, and its receptor CCR2 are more abundantly expressed in WML than in GML of MS patients. To this end, we analyzed CCL2 and CCR2 expression in the hippocampus, comprising WML and GML,of post-mortem MS patients, and of control subjects. CCL2 and CCR2 mRNA were significantly increased in demyelinated MS hippocampus. Semi-quantification of CCL2 and CCR2 immunoreactivity showed that CCL2 is present in astrocytes only in active WML. CCR2 is upregulated in monocytes/macrophages or amoeboid microglia in active WML, and in ramified microglia in active GML, although to a lesser extent. As a follow-up, we observed a significantly increased CCL2 production by WM-, but not GM-derived astrocytes upon stimulation with bz-ATP in vitro. Finally, upon CCL2 stimulation, GM-derived microglia significantly increased their proliferation rate. We conclude that within hippocampal lesions, CCL2 expression is mainly restricted to WML, whereas the receptor CCR2 is upregulated in both WML and GML. The relative absence of CCL2 in GML may explain the lack of infiltrating immune cells in this type of lesions. We propose that the divergent expression of CCL2 and CCR2 in WML and GML explains or contributes to the differences in WML and GML formation in MS.


Subject(s)
Chemokine CCL2/genetics , Gray Matter/metabolism , Hippocampus/pathology , Multiple Sclerosis/pathology , Receptors, CCR2/genetics , White Matter/metabolism , Adenosine Triphosphate/analogs & derivatives , Adenosine Triphosphate/pharmacology , Adult , Aged , Animals , Animals, Newborn , Bromodeoxyuridine/metabolism , Cell Proliferation/drug effects , Cell Proliferation/genetics , Cells, Cultured , Chemokine CCL2/metabolism , Female , Gene Expression/drug effects , Histocompatibility Antigens Class II/metabolism , Humans , Male , Middle Aged , Myelin Basic Protein/genetics , Myelin Basic Protein/metabolism , Neuroglia/metabolism , Platelet Aggregation Inhibitors/pharmacology , Rats , Rats, Wistar , Receptors, CCR2/metabolism
3.
Ann Neurol ; 73(5): 637-45, 2013 May.
Article in English | MEDLINE | ID: mdl-23595422

ABSTRACT

OBJECTIVE: Hippocampal demyelination, a common feature of postmortem multiple sclerosis (MS) brains, reduces neuronal gene expression and is a likely contributor to the memory impairment that is found in >40% of individuals with MS. How demyelination alters neuronal gene expression is unknown. METHODS: To explore whether loss of hippocampal myelin alters expression of neuronal microRNAs (miRNAs), we compared miRNA profiles from myelinated and demyelinated hippocampi from postmortem MS brains and performed validation studies. RESULTS: A network-based interaction analysis depicts a correlation between increased neuronal miRNAs and decreased neuronal genes identified in our previous study. The neuronal miRNA miR-124 was increased in demyelinated MS hippocampi and targets mRNAs encoding 26 neuronal proteins that were decreased in demyelinated hippocampus, including the ionotrophic glutamate receptors AMPA2 and AMPA3. Hippocampal demyelination in mice also increased miR-124, reduced expression of AMPA receptors, and decreased memory performance in water maze tests. Remyelination of the mouse hippocampus reversed these changes. INTERPRETATION: We establish here that myelin alters neuronal gene expression and function by modulating the levels of the neuronal miRNA miR-124. Inhibition of miR-124 in hippocampal neurons may provide a therapeutic approach to improve memory performance in MS patients.


Subject(s)
Demyelinating Diseases/pathology , Gene Expression Regulation/physiology , Hippocampus/pathology , Memory Disorders/pathology , MicroRNAs/metabolism , Neurons/metabolism , Receptors, AMPA/metabolism , Animals , Cuprizone/toxicity , Demyelinating Diseases/etiology , Disease Models, Animal , Gene Expression Regulation/drug effects , Hippocampus/metabolism , Humans , Immunosuppressive Agents/toxicity , Memory Disorders/etiology , Mice , MicroRNAs/genetics , Monoamine Oxidase Inhibitors/toxicity , Multiple Sclerosis/chemically induced , Multiple Sclerosis/complications , Multiple Sclerosis/pathology , Postmortem Changes , RNA, Messenger/metabolism , Receptors, AMPA/genetics , Sirolimus/toxicity
SELECTION OF CITATIONS
SEARCH DETAIL
...